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1. Introduction
The antimicrobial resistance (AMR) crisis is attributable, 
among other things, to massive use of antibiotics for human 
and animal health, and also to the drying up of the antibiotic 
discovery pipeline. By 2050 more people will die in the 
world because of AMR than any other illness according 
to different official sources (O’Neill, 2016). AMR involving 
methicillin-resistant Staphylococcus aureus (MRSA) 
have been reported in the hospital environment as being 
responsible for a high number of deaths (Dumitrescu et 
al., 2010; Köck et al., 2010). MRSA is a successful modern 
pathogen, living as a commensal and transmitted in 
both health-care and community settings. This harmful 
pathogen is a leading cause of clinical conditions, such as 
bacteraemia, endocarditis, skin and soft tissue infections, 
bone and joint infections and various hospital-acquired 
infections. This pathogen is still posing serious clinical 
menace, with high morbidity and mortality rates (Turner 
et al., 2019). Treatment options for MRSA are limited and 
several antimicrobials are under development, including 
vaccination as preventive measure (Lee et al., 2018). Of 
note, MRSA has become a therapeutic challenge, even 
though antibiotics like teixobactin, with a distinct mode of 
action from methicillin, exist (Ling et al., 2015). Discovery 
and development of new antibiotics has not been of high 
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Abstract
Bacteriocins have been steadily reported as potential agents that may contribute, in different ways, to overcome 
antimicrobial drug resistance. Here, holoxenic NMRI-F mice microbiota, their body weight recovery and 
histopathological alterations of organs like colon, spleen and liver were examined in mice intraperitoneally infected 
with 108 cfu of a clinical methicillin-resistant Staphylococcus aureus (MRSA-1), and treated with enterocin DD14 
alone (165 mg/kg), erythromycin alone (100 mg/kg) or their combination. Animals that received both antimicrobials 
presented a better body weight recovery than other groups. Less pronounced histopathological alterations were 
observed in mice MRSA-infected and treated with bacteriocin than in those MRSA-infected but untreated or MRSA-
infected and treated with erythromycin. Noteworthy, these alterations were absent when mice were treated with 
MRSA-infected and treated with both antibacterial agents. Furthermore, the genus richness was significantly lower in 
mice infected and treated with erythromycin, compared to mice infected and treated with both antimicrobials. The 
beta-diversity analysis showed that non-infected mice and those infected and treated with both antimicrobials, stand 
apart from the other groups as supported in a NMDS model. This in vivo study shows the relevance of bacteriocin, 
or bacteriocin-antibiotic formulation in protecting colonic, liver and spleen soft tissues and controlling the mouse 
gut microbiota, following MRSA infection.
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priority during the last decades, which could be partially 
explained by lack of investment incentive due to continuing 
lack of success.
To help curb AMR, new antibiotics and other therapeutic 
options are needed. Antimicrobial peptides (AMPs) stand 
as key alternatives to fading antibiotics and could rekindle 
the drying pipeline. AMPs possess similar, or even better 
effective activity profiles than traditional antibiotics (Seo et 
al., 2012), in spite their sensibility to proteolytic and gastric 
degradation (Renukuntla et al., 2013). The World Health 
Organization is presently calling for a groundbreaking 
action to avert this AMR crisis. International agencies and 
experts are also calling for immediate and coordinated 
action to tackle AMR. In this perspective, the global action 
encourages not only research of new antibiotics, in spite of 
industry recalcitrance, but also fosters implementation of 
key alternatives like phage therapy, faecal transplantation 
and antimicrobial peptides.
AMPs are produced by all living cells, as part of their 
innate immune system (Mishra et al., 2017), and do play 
a role in the protection of the host-cells against invading 
pathogens (Spencer et al., 2014). AMPs are endowed with 
intrinsic antibiotic activities, and are foreseen to replace 
fading or help improving their activities through synergistic 
interactions (Lei et al., 2019). Bacteriocins are ribosomally 
synthesised by both Gram-negative and Gram-positive 
bacteria (Drider and Rebuffat, 2011), as well as Archea 
(Kumar and Tiwari, 2017). Applications of bacteriocins, 
mainly those produced by lactic acid bacteria (LAB-
bacteriocins), were limited to the food industry as food 
preservatives (Chen and Hoover, 2003; O’Connor et al., 
2020), and the lantibiotic nisin is presently the only LAB-
bacteriocin to be qualified by the FDA (US Food, Drug 
and Administration) as food-preservative E234. The last 
decades has witnessed a steadily increasing number of 
studies dedicated to the potential use of LAB-bacteriocins 
as therapeutics. Indeed, these molecules are gaining more 
and more interest, and their momentum to treat multi-
drug species, in humans and animals is increasing day by 
day (Cotter et al., 2013; Meade et al., 2020; Vieco-Saiz et 
al., 2019).
Recently, we established the capabilities of the bacteriocins 
enterocin 28 (DD28), and enterocin 93 (DD93) to potentiate 
the in vitro activity of erythromycin against a MRSA-1 
strain (Al Atya et al., 2016). Interestingly, this synergistic 
interaction was also observed for enterocin 14 (DD14), when 
added to erythromycin. Of importance, the DNA sequences 
of EntDD14, EntDD28 and EntDD93 were identical 
(unpublished data). Of note, further studies were performed 
only on EntDD14, namely, genome sequencing and analysis 
(Belguesmia et al., 2017), and also by identification of the 
peptide amino acid sequence of this bacteriocin (Caly et 
al., 2017). These studies collectively enabled us to classify 
EntDD14, as a leaderless class IIb bacteriocin. To extend our 
knowledge on the potential use of this in vitro synergistic 
bacteriocin-antibiotic interaction against the MRSA-1 
strain, we looked at the effects of EntDD14-erythromycin 
combination in vivo using mice models. To that purpose, 
the NMRI-F mice were examined for the body weight 
recovery; microbiota stability and histological alterations 
of the intestine; spleen and liver; after their MRSA-infection 
and treatment with antibiotic (erythromycin), bacteriocin 
(EntDD14) or their combination.
2. Materials and methods
EntDD14 preparation and antibiotic activity
The bacteriocinogenic Enterococcus faecalis 14 was 
grown overnight at 37 °C, in Brain Heart Infusion (BHI) 
broth (Fluka Analytical, Steinheim, Germany). Then, the 
culture was centrifuged (8,000×g, 4 °C, 10 min). 40 ml of 
the resulting cell-free supernatant (CFS) were passed, at 
room temperature (20-25 °C) with a flow rate of 1 ml/min, 
through a C18 solid phase extraction (SPE) cartridge 
containing octadecyl silica as a filler to retain non-polar 
compounds by strong hydrophobic interaction (Agilent, 
Santa Clara, CA, USA). Several washing steps with 40 ml 
of eluents containing successively 10, 20, 30 and 40% (v/v) 
of acetonitrile, mixed with deionised water, permitted the 
removal of contaminants. The semi-purified EntDD14 was 
eluted with 50% (v/v) of acetonitrile. This active fraction 
was dried using a SpeedVac and resuspended in ultrapure 
water. The DD14 concentration was determined by the 
Bradford protein assay (Bradford, 1976), whereas its total 
activity was assessed as described by Dabard et al. (2001). 
Then, and according to the protocol described by Al Atya 
et al. (2016), the minimal inhibitory concentrations (MICs) 
of EntDD14 or erythromycin (Ery) were determined as well 
as their fractional inhibitory concentration index (FICI) to 
assess their interaction.
Animal design, diet and housing conditions
Holoxenic NMRI-F (Naval Medical Research Institute) 
strain of mice were obtained from the Pasteur Institute of 
Algiers (Algeria). Thus, 35 female mice (NMRI-F), with a 
weight of 30 g were randomly assigned to 5 different groups 
(G1, G2, G3, G4 and G5). They were housed individually in 
metal cages under controlled room temperature (20±2 °C), 
humidity (50±5%), constant 12 h/12 h light/dark cycle and 
fed with mouse diet obtained from a local company (ONAB, 
Bejaia, Algeria), and water for 1 week ad libitum before the 
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Challenge tests
The antibacterial agents, namely erythromycin and 
EntDD14, were dissolved in 0.9% (v/v) saline sterile water. 
The animals were divided in five groups (G1 to G5). G1 
was used as control, the other four groups were challenged 
intraperitoneally (right side) with 100 µl of MRSA-1 strain 
at 109 cfu/ml. Then, 1 h later, all groups, except G2, received 
a single dose of a solution of 100 µl of erythromycin at 
100 mg/kg (G3), or EntDD14 at 165 mg/kg (G5) or of 
both of them (G4) (left-side). Following these challenge 
tests and administration of the antibacterial agents above-
cited, animals were regularly examined for adverse effects 
and morbidity during 96 h. Their body weights were 
daily registered. At the end of the 96 h of experimental 
monitoring, 5 different samples of faeces from each group 
were randomly taken for DNA extraction and microbiota 
analyses.
Ethical procedure
Animals were sacrificed and one animal per group was used 
for histological examinations following eosin-staining of 
organs, such as colon, liver and spleen. All international and 
national applicable guidelines were scrupulously respected 
for animal care and welfare.
Histological sections examinations
Following animal euthanasia and dissection, liver, spleen 
and colon were removed and immediately put into 10% 
(v/v) of neutral-buffered formalin solution. The histological 
sections were prepared at a private laboratory of anatomy, 
cytology and pathology (Bejaia, Algeria). The inclusion of 
the sections was carried out as previously reported (Lussier, 
1989), and the staining of the slides was performed using the 
haematoxylin-eosin procedure (Sobotta and Welsch, 2000).
DNA extraction and purification
Total bacterial DNA was extracted from 25 mg of faeces 
using a QIAamp PowerFecal extraction kit (Qiagen, 
Venlo, the Netherlands), according to the manufacturer’s 
recommendations. A first mechanical lysis step of 5 min 
using lysing matrix E tubes (MP Biomedicals, Illkirch, 
France) and extraction kit lysis buffer was applied. The 
DNA was then diluted with DNAse and RNAse-free 
water and its concentration and purity were evaluated by 
optical density at 260/280 nm using a Nano Drop ND-1000 
spectrophotometer (Isogen, St-Pieters-Leeuw, Belgium). 
Then, DNA samples were stored at -20 °C until they were 
used for the sequencing analysis.
16S rDNA high throughput amplicon sequencing
PCR-amplification of the V1-V3 region of the 16S 
rDNA, and library preparation were performed with the 
following primers (with Illumina overhand adapters), 
forward (5’-GAGAGTTTGATYMTGGCTCAG-3’), and 
reverse (5’-ACCGCGGCTGCTGGCAC-3’). Each PCR 
product was purified with the Agencourt AMPure XP 
beads kit (Beckman Coulter, Pasadena, CA, USA) and 
submitted to a second PCR round for indexing, using the 
Nextera XT index primers 1 and 2. After purification, PCR 
products were quantified using the Quant-IT PicoGreen 
(ThermoFisher Scientific, Waltham, MA, USA) and 
diluted to 10 ng/µl. A final quantification, by qPCR, of 
each sample in the library was performed using the KAPA 
SYBR® FAST qPCR Kit (KapaBiosystems, Wilmington, MA, 
USA) before normalisation, pooling and sequencing on a 
MiSeq sequencer using v3 reagents (Illumina, San Diego, 
CA, USA). Positive control using DNA from 20 defined 
bacterial species and a negative control (from the PCR 
step) were included in the sequencing run. Raw amplicon 
sequencing libraries were submitted to the NCBI database 
under bioproject number PRJNA623490.
Sequence analysis and 16S rDNA profiling
Sequence reads processing was performed as previously 
described using MOTHUR software package v141.1 
(Schloss et al., 2009) and VSEARCH algorithm for chimera 
detection (Rognes et al., 2016). A clustering distance of 0.03 
was used for operational taxonomic unit (OTU) generation. 
16S rDNA reference alignment and taxonomical assignment 
were based upon the SILVA database (v1.32) of full-length 
16S rDNA sequences (Quast et al., 2013).
Data analysis
Subsample datasets were obtained and used to evaluate 
ecological indicators (Goods Coverage, Chao richness 
index and reciprocal Simpson microbial diversity of the 
samples) and beta-diversity (using a distance Bray-Curtis 
dissimilarity matrix) using MOTHUR. Beta-diversity was 
visualised with a Bray-Curtis dissimilarity matrix based 
non-parametric dimensional Scaling (NMDS) model using 
vegan (Oksanen et al., 2019) and vegan3d (Oksanen et al., 
2018) packages on R. Sample clustering and beta-dispersion 
were respectively assessed on Bray-Curtis dissimilarity 
matrix with AMOVA and HOMOVA tests using MOTHUR 
(using 10,000 iterations on the rarefied table).
Statistical analysis
All results were expressed as mean ± standard deviation. 
Statistical analysis, except for microbiota and mouse 
bodyweight analyses, was performed using the one-way 
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5.5 (1999 edition) software (Statsoft, Tulsa, OK, USA). 
Differences among means were detected by paired 
Student’s test. Values of P<0.05 were considered statistically 
significant. Statistical analysis of mouse body weights was 
conducted in GraphPad prism v6.1 (La Jolla, CA, USA), 
one way ANOVA was applied with Tukey’s test for post 
comparison (P<0.05). Microbial population structure and 
microbial population abundance difference between groups 
were assessed with the Kruskal-Wallis non parametric test 
followed by paired-tests corrected by Benjamini, Krieger, 
Yekutieli False Discovery Rate using PRISM 7 (Graphpad 
Software), differences were considered significant for a 
q-value <0.01.
3. Results
EntDD14 and erythromycin enabled synergistic 
interaction in vitro against MRSA-1
MRSA-1 strain was resistant to erythromycin (MIC 16 μg/
ml) according to the CA-SFM guideline (CA-SFM, 2019). 
Of note, the MIC of erythromycin decreased from 16 to 
1 μg/ml, in the presence of EntDD14, arguing a potential 
synergistic interaction. Indeed, this interaction was 
confirmed by the FIC value 0.313. Antibacterial activities 
of EntDD14, erythromycin and their combination are given 
in Table 1. Interpretation of these data were performed as 
reported by Petersen et al. (2006).
Animals infected with MRSA-1 and treated with 
erythromycin + DD14 show a better body weight recovery 
than groups G2, G3 and G5
Results showed that the mouse body weights were not 
significantly different between groups during the first three 
days of the experiment but at day 4 all the treatments led to 
a significant body weight decrease when compared to G1 
(Supplementary Figure S1). However, the mice for which 
EntDD14 and erythromycin were administrated, alone (G5) 
or in association (G4), presented a significantly higher body 
weight than mice from G2. Moreover, the mice treated by 
both EntDD14 + erythromycin (G4) appeared to be less 
affected than other mice treated with either drug alone. 
The P-values obtained were 0.0688 (G4 versus G5), and 
0.0375 (G4 versus G5).
Histopathological examination revealed severe 
alterations in G2 and G3 mice
The histological sections were analysed for the main organs, 
namely colon, spleen and liver. These examinations revealed 
G1 presented a preserved colic architecture with normal 
height crypts and devoid of any inflammatory and/or 
ulcerated signs (Figure 1 – IA). Nevertheless, intraperitoneal 
administration of MRSA-1 strain to mice caused villous 
atrophy, and other adverse effects like infectious and 
inflammatory symptoms, outlined by a mesenteric 
lymphadenopathy and ileal intestinal mucosa, respectively 
(Figure 1 – IB). These adverse effects were also observed 
for animal infected with MRSA-1 strain and treated with 
erythromycin (Figure 1 – IC). Architecture of crypts was 
mostly impaired, and inflammatory signs with lymphocytic 
infiltration were observed (Figure 1 – IC). Of note animals 
challenged with MRSA-1 strain and treated with EntDD14 
exhibited less pronouncedly these adverse effects, as 
indicated on Figure 1 – IE. Importantly, when mice were 
challenged with MRSA-1 and concomitantly treated with 
both antibacterial agents, EntDD14+Erythromycin, a 
normal anatomy was observed. This normality, as seen 
on Figure 1 – ID, is associated with normal intestinal 
mucosa and intact villosities. This anatomy and cellular 
architecture are fairly equivalent to those from the animal 
group used as positive control. Despite that the MRSA-1 
strain is resistant to erythromycin, and EntDD14 weakly 
Table 1. Minimum inhibitory concentrations (MICs) of antimicrobials and their association against methicillin-resistant Staphylococcus 
aureus (MRSA)-S1.1,2,3
Strain DD14 (µg/ml) Ery (µg/ml) DD14-Ery (µg/ml) FICDD144 FICEry5 FICI6
MRSA-S1 154 16 38.5/1 0.25 0.063 0.313
1 Minimum inhibitory concentrations (MICs) are defined as the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism 
after overnight incubation.
2 FIC index = (MIC of DD14 in association/MIC of DD14 alone) + (MIC of erythromycin in association/MIC of erythromycin alone). In antimicrobial 
association, Petersen et al. (2006) defined synergy as ∑FIC≤0.5, additivity as 0.5<∑FIC≤1, indifference as 1<∑FIC ≤ 4 and antagonism as ∑FIC>4.
3 DD14 = enterocin DD14; Ery = erythromycin; FIC = fractional inhibitory concentration; FICI = fractional inhibitory concentration index.
4 FICDD14 = MIC of DD14 in association/MIC of DD14 alone.
5 FICEry = MIC of Ery in association/MIC of Ery alone.
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active, their association enabled synergistic interaction in 
vitro (Table 1). These results convey the potency and utility 
of such combination in fighting staphylococcal infections.
The histological sections of liver were studied similarly. As 
depicted on Figure 1 – IIA, the animal from the control 
group presented a well conserved cellular architecture, 
which is typically present in intact organ. Nevertheless, this 
architecture was affected when mice were intraperitoneally 
challenged with the MRSA-1 strain. Indeed, symptoms of 
liver injury were marked by several adverse events such 
as haemorrhage, increase in both cytoplasm density, and 
chromatin content, binucleation process, centrolobular 
hepatic necrosis and inflammatory reactions (Figure 1 – 
IIB). Of note, centrolobular hepatic necrosis was markedly 
associated with congested veins, while inflammatory 
reaction was, in turns, associated with hepatocyte 
degeneration (Figure 1 – IIB). The histological analysis 
revealed overall similar adverse effects in mice infected with 
the MRSA-1 strain and treated with erythromycin (Figure 
1 – IIC). Accordingly, necrosis was noticeably represented 
by the disappearance of caniculi and loss of the zone of 
drainage, whereas cellular intoxication was marked by loss 
of polygonal and radial hepatic cell shapes, cell junctions/
ends as well as bi-nucleation process in the nucleus, and 
increased chromatin concentration (Figure 1 – IIC). 
These lesions were less pronounced in mice infected with 
MRSA-1 strain and treated with EntDD14 alone (Figure 
1 – IIE). Nevertheless, mice infected with MRSA-1 strain 
and treated by EntDD14+erythromycin were less afflicted 
since signs of necrosis were insignificant, as noted with 
a faint vascular congestion, and increase in the nuclear 
chromatin concentration (Figure 1 – IID). Mice from group 
1 were used as baseline control, since they had received 
no antibacterial agent and/or MRSA-1 strain. Histological 
sections of spleen from an animal taken from this group 
were normal, with well-organised cellular architecture and 
typically healthy spleen cells (Figure 1 – IIIA). Similar to 
other organs, challenge and treatment caused modifications, 
which were treatment-dependent. Signs of severe adverse 
effects, supporting a vascular affection, were observed 
in mouse of G2. These signs included manifest venous 
congestion of sinusoids, and haemorrhagic suffusion. 
In addition, infection and inflammatory reactions were 
observed. They showed on one hand a myeloid metaplasia 
and abundance of megakaryocytes, and on the other hand 
granulo-vitreous degeneration (Figure 1 – IIIB). However, 
when mice came from groups challenged with MRSA-
1 and receiving erythromycin or EntDD14, only signs 
of bacterial infection characterised by a splenomegaly 
were noticeably observed (Figure 1 – IIIC and IIID). The 
histological analyses did not show, at the cellular level, clear 
Figure 1. Histological examination and eosin-stained sections of organs: colon (I), liver (II) and spleen (III). Tissues were from 
mice G1 (A) (–, –, –), G2 (B) (+, –, –), G3 (C) (+, +, –), G4, (D) (+, +, +) and G5 (E) (+, –, +). Organs are indicated on the right side of 
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differences with that of the group I (Figure 1 – IIIA, IIIC and 
IIIE). Nonetheless, the spleen tissues of mice infected with 
MRSA-1 strain and treated with both antibacterial agents, 
EntDD14+Erythromycin, displayed similar organisation to 
those of the animal from group 1, that was used as control 
baseline (Figure 1 – IIID).
Analysis of faecal microbiota
From the 25 libraries, we obtained 3,204,042 raw reads 
and 1,690,250 reads after cleaning and chimera detection 
(median length of 503 bp). We retained a subsampled pool 
of 10,000 reads per sample to proceed with OTU binning 
(0.03 cut-off ) for a total of 5,945 OTUs. Mean sampling 
Good’s coverage was 99.87%, with no statistical difference 
between groups. Notably, the faecal microbial population 
structure was assessed at the genus level. Intrinsic diversity 
analysis revealed that genus richness was significantly lower 
in G2, compared to mice from G1 and G4 (Supplementary 
Figure S2A). Beta-diversity analysis showed that G1, and 
G4, stand apart from the other groups as illustrated in a 
NMDS model (K=3, stress 0.04) (Supplementary Figure 
S2B). This clustering, however, is only significant for G1 
versus G2 (AMOVA test, P=0.00396). Moreover G4 versus 
G2 does not reach significance but is close (P=0.00689).
The alpha biodiversity index Shannon is a continuous 
variable with a lower bound of zero and no upper bound. 
Higher is the value, greater is the diversity. As seen in 
Supplementary Figure S2A, the level of diversity declined 
following the infection with MRSA-1 strain, and the 
Shannon’s index declined significantly compared to the 
control. However, the diversity was partly recovered after 
administration of any drug alone, raising the biodiversity at 
the same level. However, the noticeable effect was obtained 
when these drugs were administered concomitantly. The 
Shannon index increased, reflecting an enhancement of 
the richness at the genus level.
Supplementary Figure S3 indicates that Bacteroidetes and 
Firmicutes are the prevailing phyla as expected for faecal 
microbiota. At the genus level, the main genera in G1, G2, 
G3 and G5 belong to the Firmicutes with Lactobacillus, 
Enterococcus and Turicibacter being present. However, 
in G1 and G4, the most abundant population belong to 
the Bacteroidetes with Alistipes genus and population 
belonging to the Prevotellaceae and Muribaculaceae 
families. Moreover, Kruskal-Wallis H test evaluation for 
the population abundance in the different groups was 
performed and highlighted several populations of interest 
(Supplementary Table S1). Mainly we confirmed the shift 
Firmicutes/Bacteroidetes between G1 and G2 (q<0.0001) 
but also between G4 and the other infected groups G2, G3 
and G5 (q<0.0001). These differences can also be found at 
the genus level with Lactobacillus being significantly more 
abundant in G2, G3 and G5 compared to G1 and G4. The 
Enterococcus population is also more abundant in G3 and 
G5 compared to the others.
4. Discussion
To bolster antibiotic stewardship initiatives, the LAB-
bacteriocins are gaining more and more interest for 
therapeutic applications (Dischinger et al., 2014; Meade 
et al., 2020; Ołdak and Zielińska, 2017). With respect to 
this objective, we provide in the present study original 
data on the in vivo cytotoxicity of class IIb enterocin DD14 
(Belguesmia et al., 2017; Caly et al., 2017), and studied its 
impact on different markers as discussed below. Overall, 
studies dedicated to cytotoxicity and immunotoxicity of 
bacteriocins are very limited, in spite of the relevance of this 
aspect to food or medical applications. Nisin, which is the 
only authorised and marketed bacteriocin used as a food 
additive (E234), is the most studied model for cytotoxicity 
aspects.
The effects of EntDD14, erythromycin, or their association 
were examined in vivo using the NMRI-F mice, as 
murine model. These effects concerned markers such 
as body weight change, gut microbiota stability and 
histopathological lesions in the NMRI-F mice, challenged 
with a clinical MRSA-1 strain, and treated with EntDD14, 
erythromycin, or both. To clarify the use of these molecules, 
we suggest referring to our recently reported in vitro data, 
in which we showed that DD28 and DD93 were able to 
potentiate erythromycin against the target MRSA-1 strain 
(Al Atya et al., 2016). Importantly, the DNA sequences 
of EntDD14, EntDD28 and EntDD93 are fully identical 
(unpublished data), despite producing strains having been 
isolated from different samples (Al Atya et al., 2016; Caly 
et al., 2017). Of note, the EnDD14 was the first one which 
was fully characterised (Caly et al., 2017). In addition, all 
these bacteriocins are weakly active against the MRSA-1 
strain. Nevertheless, when added to erythromycin, any of 
these bacteriocins provides in vitro synergistic interactions 
against the MRSA-1 strain (Al Atya et al., 2016) (Table 1). 
Here, we examined the effects of EntDD14, erythromycin, 
or both, when administered intraperitoneally to NMRI-F 
mice concomitantly infected with the MRSA-1 strain. The 
route of administration of bacteriocins is a key element. 
Oral administration can be counterproductive because of 
conditions met during the gastrointestinal transit, such as 
low pH, proteases, etc. These conditions are unfavourable 
to bacteriocins, and can impair their activity and stability 
(Fernandez et al., 2013). For example, Kheadr et al. (2010) 
outlined the instability of pediocin PA-1/AcH in the 
dynamic in vitro TIM model, which mimics the upper 
human gastrointestinal tract.
Nevertheless, the oral administration of bacteriocins can 
gain insight into their safety aspects. Thus, Frazer et al. 
















































































 Bacteriocins as therapeutics and microbiota regulators
Beneficial Microbes 12(3) 301
safety of this bacteriocin. However, de Almeida Vaucher et 
al. (2011) reported histopathological alterations of spleen, 
skin and liver following oral nisaplin administration to 
mice. On the other hand, Sahoo et al. (2017) showed that 
mice receiving orally and daily 0.5 mg/kg of bacteriocin 
TSU4 for 21 days, showed no deaths, and were devoid of 
any immunogenicity or toxic effect.
Furthermore, the class IIc enterocin AS 48 was 
intraperitoneally administered to BALB/c mice and the 
authors reported (Baños et al., 2019) moderate vacuolar 
degeneration in the hepatocytes, conversely to mice fed 
with nisin. However, Ketaren, et al. (2016) showed that mice 
receiving intraperitoneally high amounts of pediocin N6 (up 
to 20,000 mg/kg) did not show any sign of acute toxicity.
In the present study, EntDD14 was administrated 
intraperitoneally to NMRI-F mice, to avoid proteolytic 
and gastric degradation of EntDD14. Additionally, this 
route was also used for administration of erythromycin, 
and challenge with the MRSA-1 strain to allow its rapid 
spread into the bloodstream. As reviewed by Turner et al. 
(2019), Staphylococcus aureus expresses different virulence 
factors, such as toxins, immune-evasive surface factors and 
enzymes that promote its tissue invasion. Other harmful 
toxins like exfoliative toxins, adhesins and haemolysins were 
reported (Malachowa and DeLeo, 2010). These authors 
revealed that some MRSA strains can utilise bacteriocins 
as MGE (mobile-genetic-elements) to inhibit competing 
or commensal bacteria (Malachowa and DeLeo, 2010). 
In the present study, no death was registered during 4 
days of experimental analysis and monitoring, in spite of 
a dose of pathogen administrated to the mice. This can be 
explained by different factors, such as strain adaptation, 
genetic reorganisation and finally loss of the virulence traits 
(Mizobuchi et al., 1994).
In terms of the body weight incremental, we noticed at the 
end of 4 days experimental analysis that the mice from G4 
were less affected than those from other infected groups G2, 
G3 and G5. Examination of histological sections revealed 
severe histopathological damage in the colon, spleen 
and liver from the mice of G2 and G3. These symptoms 
and signs of necrosis, cellular toxicity and inflammation 
observed in G2 and G3 can be attributed to many factors 
including toxins secreted locally by MRSA-1 and their 
dissemination via the blood circulation. In MRSA-infected 
mice treated with erythromycin alone (G3), these adverse 
effects were expected because this strain is resistant to this 
antibiotic (Al Atya et al., 2016) (Table 1). Erythromycin 
is used for treatment of nosocomial infections mostly 
caused by S. aureus, but because surviving bacteria are 
frequently found most patients are recommended to receive 
combination therapy of erythromycin with other agents 
active against S. aureus. Erythromycin is suitable for treating 
Gram-positive infections in humans. By increasing the 
concentration of erythromycin to 600 mg/g of faeces, its 
spectrum has been shown to be extended and became active 
against some intestinal Gram-negative bacteria such as 
those from Enterobactericeae family (Hartley et al., 1978). 
The histopathological alterations reported in mice from G2 
and G3 persisted, but to a lesser extent to the animals in G5, 
which had been infected and EntDD14 treated. Finally, these 
clinical signs were cleared following treatment of infected 
mice with erythromycin+ EntDD14. The cationic nature 
of LAB-bacteriocins can prejudice their effectiveness, 
because they can bind to blood components (Ghobrial et al., 
2010). Data gathered here indicate the absence of toxicity 
of EntDD14, and revealed that erythromycin+EntDD14 
is a suitable association that provides protection from 
deleterious effects of MRSA.
With respect to the microbiota aspects, it should be 
remembered that although antibiotics are invaluable 
weapons for eliminating malevolent pathogens, they can 
also induce long-lasting deleterious effects on the host 
such as the destabilisation of the microbiota, leading to 
dysbiosis (Lagier et al., 2012; Lange et al., 2016). The impact 
of antibiotics on the gut microbiota depends on its route of 
administration, dose and time of administration (Ruppé et 
al., 2018). Thus, we looked at the impacts of erythromycin, 
EntDD14, or their association on the NMRI-F mouse gut 
microbiota under different experimental conditions. Firstly, 
we looked at the phyla composition in each mouse group. 
The Firmicutes/Bacteroidetes ratio (F/B) is a key factor in 
mouse obesity (Ley et al., 2005), and this is also consistently 
confirmed for humans (Barlow et al., 2015; Sweeney and 
Morton, 2013).
Metagenomic analyses of the faecal samples from G1 
revealed, amongst other phyla, Epsilonbacteteraeota, 
Lentisphaerae and Proteobacteria. Epsilonbacteteraeota 
phylum has been introduced into the bacterial taxonomy, 
following re-classification of class Epsilonproteobacteria 
(Waite et al., 2017), whereas the Lentisphaerae phylum, 
has been included in the PVC super-phylum, which initially 
contained three phyla Planctomycetes, Verrucomicrobia and 
Chlamydiae (Fuerst, 2013). In the present study, a shift in 
the gut faecal composition occurred following infection 
of mice with MRSA-1strain (G2), and their subsequent 
treatment with erythromycin (G3), or EntDD14 (G5).
The Proteobacteria phylum has been reported to be 
associated with obesity complex disease (Bai et al., 2019; 
Rizzatti et al., 2017). Proteobacteria, qualified as key 
dysbiosis players, are not only present in the gut and stools 
but also in others human body sites, like skin, oral cavity, 
tongue or vaginal tract (Huttenhower et al., 2012). This 
phylum also contains pathogens such as Brucella, Rickettsia, 
Bordetella, Neisseria, Escherichia, Shigella, Salmonella, 
Yersinia, and Helicobacter, which are associated with both 
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2017; Maharshak et al., 2013). The metagenomic analyses 
performed here showed that faecal samples from mice of 
G4 contained more Bacteriodetes than Firmicutes. This 
is an important point because mice from G4 exhibited 
greater body weight recovery profiles (Supplementary 
Figure S1), and earlier studies reported a predominance 
of Bacteroidetes in overweight and obese individuals 
(Schwiertz et al., 2010), and a positive correlation between 
the faecal concentrations of Bacteroides and the body 
mass index (Ignacio et al., 2016). Deeper analyses of 
these metagenomic data revealed a relative abundance of 
Helicobacter, Lachnospiraceae, Bacteroidales/Bacteroides, 
Prevotellaceae and Muribaculaceae. Interestingly, 
Muribacaculaceae is known to be the dominant bacterial 
group in the mouse gut (Seedorf et al., 2014). Nevertheless, 
this profile has been modified in other groups (G2, G3, 
G4 and G5), being noteworthy the relative abundance of 
probiotic genera, such as Lactobacillus and Enterococcus 
in G3 and G5.
5. Conclusions
During this study we established that Holoxenic NMRI-F 
mice infected with the MRSA-1 strain, and treated with 
erythromycin, EntDD14 or both of them, responded 
differently based on the clinical parameters used. 
Interestingly the MRSA-infected mice concomitantly 
treated with erythromycin and EntDD14 showed the best 
body weight recovery. Of note, this bacteriocin-antibiotic 
combination enabled protection of the soft tissue of 
organs such as colon, liver and spleen, against the MRSA-
1 strain. Moreover the faecal microbiota composition, 
and more particularly the beta-diversity analysis revealed 
a convergence between the uninfected mice and those 
treated with MRSA-infected and treated concomitantly 
with bacteriocin-antibiotic. These new advances constitute 
a new step in the valorisation of LAB-bacteriocins as 
therapeutic agents. This unique study carried out in vivo on 
the Holoxenic mice models permitted to show the clinical 
and metagenomic alterations following mice infection 
with MRS-1 strain and their treatment with erythromycin, 
EntDD14 and both of them. To strengthen this approach, 
further clinical investigations using other molecules and 
infection models will be tested in the near future.
Supplementary material
Supplementary material can be found online at https://doi.
org/10.3920/BM2020.0155.
Table S1. Abundance of bacterial taxa expressed in 
percentage that are statistically impacted by the MRSA 
challenge or the post-challenge treatment, as determined 
by 16S amplicon sequencing.
Figure S1. Body weight evolution during animal 
experimentation and monitoring.
Figure S2. Intrinsic bacterial genus diversity, genus richness 
and evenness deduced respectively from reciprocal Simpson 
Index, Chao1 index and Simpson index (A). Non-metric 
dimensional scaling model with three axis of the five mouse 
groups (B).
Figure S3. Changes in microbial populations in the faecal 
content, assessed by 16S profiling.
Acknowledgements
The authors would like to thank la Région des Hauts-de-
France for supporting part of this work, through CPER/
FEDER Alibiotech (2016/2021). The authors are indebted to 
Dr. Steve W Elson, Dr. Bruce Seal (Oregon State University) 
and Prof. Luis A Nero (Universidade Federal de Viçosa, 
Brazil) for critical reading of the manuscript.
Conflict of interest
The authors declare no competing interest
References
Al Atya, A.K., Belguesmia, Y., Chataigne, G., Ravallec, R., Vachée, A., 
Szunerits, S., Boukherroub, R. and Drider, D., 2016. Anti-MRSA 
activities of enterocins DD28 and DD93 and evidences on their role 
in the inhibition of biofilm formation. Frontiers in Microbiology 7: 
817. https://doi.org/10.3389/fmicb.2016.00817
Bai, J., Hu, Y. and Bruner, D.W., 2019. Composition of gut microbiota 
and its association with body mass index and lifestyle factors in a 
cohort of 7-18 years old children from the American Gut Project. 
Pediatric Obesity 14: e12480. https://doi.org/10.1111/ijpo.12480
Baños, A., García, J.D., Núñez, C., Mut-Salud, N., Ananou, S., Martínez-
Bueno, M., Maqueda, M., and Valdivia E., 2019. Subchronic toxicity 
study in BALBc mice of enterocin AS-48, an anti-microbial peptide 
produced by Enterococcus faecalis UGRA10. Food Chemical 
Toxicology 132: 110667. https://doi.org/10.1016/j.fct.2019.110667
Barlow, G.M., Yu, A. and Mathur, R., 2015. Role of the gut microbiome 
in obesity and diabetes mellitus. Nutrition in Clinical Practice 30: 
787-797. https://doi.org/10.1177/0884533615609896
Belguesmia, Y., Leclère, V., Duban, M., Auclair, E. and Drider, D., 
2017. Draft genome sequence of Enterococcus faecalis DD14, a 
bacteriocinogenic lactic acid bacterium with anti-Clostridium 
activity. Genome Announcements 5. https://doi.org/10.1128/
genomeA.00695-17
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation 
of microgram quantities of protein utilizing the principle of protein-

















































































 Bacteriocins as therapeutics and microbiota regulators
Beneficial Microbes 12(3) 303
Caly, D.L., Chevalier, M., Flahaut, C., Cudennec, B., Al Atya, A.K., 
Chataigné, G., D’Inca, R., Auclair, E. and Drider, D., 2017. The 
safe enterocin DD14 is a leaderless two-peptide bacteriocin 
with anti-Clostridium perfringens activity. International Journal 
of Antimicrobial Agents 49: 282-289. https://doi.org/10.1016/j.
ijantimicag.2016.11.016
CA-SFM, 2019. CASFM/EUCAST 2019. Société Française de 
Microbiologie. https://www.sfm-microbiologie.org/2019/01/07/
casfm-eucast-2019/.
Chen, H. and Hoover, D.G., 2003. Bacteriocins and their food 
applications. Comprehensive Reviews in Food Science and Food 
Safety 2: 82-100. https://doi.org/10.1111/j.1541-4337.2003.tb00016.x
Cotter, P.D., Ross, R.P. and Hill, C., 2013. Bacteriocins – a viable 
alternative to antibiotics? Nature Reviews Microbiology 11: 95-
105. https://doi.org/10.1038/nrmicro2937
Dabard, J., Bridonneau, C., Phillipe, C., Anglade, P., Molle, D., Nardi, 
M., Ladiré, M., Girardin, H., Marcille, F., Gomez, A. and Fons, 
M., 2001. Ruminococcin A, a new lantibiotic produced by a 
Ruminococcus gnavus strain isolated from human feces. Applied and 
Environmental Microbiology 67: 4111-4118. https://doi.org/10.1128/
AEM.67.9.4111-4118.2001
De Almeida Vaucher, R., De Campos Velho Gewehr, C., Folmer Correa, 
A.P., Sant‘Anna, V., Ferreira, J. and Brandelli, A., 2011. Evaluation 
of the immunogenicity and in vivo toxicity of the antimicrobial 
peptide P34. International Journal of Pharmaceutics 421: 94-98. 
https://doi.org/10.1016/j.ijpharm.2011.09.020
Dischinger, J., Basi Chipalu, S. and Bierbaum, G., 2014. Lantibiotics: 
promising candidates for future applications in health care. 
International Journal of Medical Microbiology 304: 51-62. https://
doi.org/10.1016/j.ijmm.2013.09.003
Drider, D. and Rebuffat, S., 2011. Prokaryotic antimicrobial peptides 
– from genes to applications. Springer, New York, NY, USA.
Dumitrescu, O., Dauwalder, O., Boisset, S., Reverdy, M.-É., Tristan, 
A. and Vandenesch, F., 2010. Résistance aux antibiotiques chez 
Staphylococcus aureus: les points-clés en 2010. Médecine/Sciences 
26: 943-949. https://doi.org/10.1051/medsci/20102611943
Fernandez, B., Le Lay, C., Jean, J. and Fliss, I., 2013. Growth, acid 
production and bacteriocin production by probiotic candidates 
under simulated colonic conditions. Journal of Applied Microbiology 
114: 877-885. https://doi.org/10.1111/jam.12081
Frazer, A.C., Sharratt, M. and Hickman, J.R., 1962. The biological 
effects of food additives. I. Nisin. Journal of the Science of Food 
and Agriculture 13: 32-42. https://doi.org/10.1002/jsfa.2740130106
Fuerst, J.A., 2013. The PVC superphylum: exceptions to the bacterial 
definition? Antonie Van Leeuwenhoek 104: 451-466. https://doi.
org/10.1007/s10482-013-9986-1
Ghobrial, O., Derendorf, H. and Hillman, J.D., 2010. Human serum 
binding and its effect on the pharmacodynamics of the lantibiotic 
MU1140. European Journal of Pharmaceutical Sciences 41: 658-664. 
https://doi.org/10.1016/j.ejps.2010.09.005
Hartley, C.L., Clements, H.M. and Linton, K.B., 1978. Effects of 
cephalexin, erythromycin and clindamycin on the aerobic Gram-
negative faecal flora in man. Journal of Medical Microbiology 11: 
125-135. https://doi.org/10.1099/00222615-11-2-125
Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J.H., 
Chinwalla, A.T., Creasy, H.H., Earl, A.M., FitzGerald, M.G., Fulton, 
R.S., Giglio, M.G., Hallsworth-Pepin, K., Lobos, E.A., Madupu, R., 
Magrini, V., Martin, J.C., Mitreva, M., Muzny, D.M., Sodergren, E.J., 
Versalovic, J., Wollam, A.M., Worley, K.C., Wortman, J.R., Young, 
S.K., Zeng, Q., Aagaard, K.M., Abolude, O.O., Allen-Vercoe, E., 
Alm, E.J., Alvarado, L., Andersen, G.L., Anderson, S., Appelbaum, 
E., Arachchi, H.M., Armitage, G., Arze, C.A., Ayvaz, T., Baker, 
C.C., Begg, L., Belachew, T., Bhonagiri, V., Bihan, M., Blaser, M.J., 
Bloom, T., Bonazzi, V., Paul Brooks, J., Buck, G.A., Buhay, C.J., 
Busam, D.A., Campbell, J.L., Canon, S.R., Cantarel, B.L., Chain, 
P.S.G., Chen, I.-M.A., Chen, L., Chhibba, S., Chu, K., Ciulla, D.M., 
Clemente, J.C., Clifton, S.W., Conlan, S., Crabtree, J., Cutting, M.A., 
Davidovics, N.J., Davis, C.C., DeSantis, T.Z., Deal, C., Delehaunty, 
K.D., Dewhirst, F.E., Deych, E., Ding, Y., Dooling, D.J., Dugan, S.P., 
Michael Dunne, W., Scott Durkin, A., Edgar, R.C., Erlich, R.L., 
Farmer, C.N., Farrell, R.M., Faust, K., Feldgarden, M., Felix, V.M., 
Fisher, S., Fodor, A.A., Forney, L.J., Foster, L., Di Francesco, V., 
Friedman, J., Friedrich, D.C., Fronick, C.C., Fulton, L.L., Gao, H., 
Garcia, N., Giannoukos, G., Giblin, C., Giovanni, M.Y., Goldberg, 
J.M., Goll, J., Gonzalez, A., Griggs, A., Gujja, S., Kinder Haake, S., 
Haas, B.J., Hamilton, H.A., Harris, E.L., Hepburn, T.A., Herter, B., 
Hoffmann, D.E., Holder, M.E., Howarth, C., Huang, K.H., Huse, 
S.M., Izard, J., Jansson, J.K., Jiang, H., Jordan, C., Joshi, V., Katancik, 
J.A., Keitel, W.A., Kelley, S.T., Kells, C., King, N.B., Knights, D., 
Kong, H.H., Koren, O., Koren, S., Kota, K.C., Kovar, C.L., Kyrpides, 
N.C., La Rosa, P.S., Lee, S.L., Lemon, K.P., Lennon, N., Lewis, C.M., 
Lewis, L., Ley, R.E., Li, K., Liolios, K., Liu, B., Liu, Y., Lo, C.-C., 
Lozupone, C.A., Dwayne Lunsford, R., Madden, T., Mahurkar, 
A.A., Mannon, P.J., Mardis, E.R., Markowitz, V.M., Mavromatis, 
K., McCorrison, J.M., McDonald, D., McEwen, J., McGuire, A.L., 
McInnes, P., Mehta, T., Mihindukulasuriya, K.A., Miller, J.R., Minx, 
P.J., Newsham, I., Nusbaum, C., O’Laughlin, M., Orvis, J., Pagani, 
I., Palaniappan, K., Patel, S.M., Pearson, M., Peterson, J., Podar, M., 
Pohl, C., Pollard, K.S., Pop, M., Priest, M.E., Proctor, L.M., Qin, 
X., Raes, J., Ravel, J., Reid, J.G., Rho, M., Rhodes, R., Riehle, K.P., 
Rivera, M.C., Rodriguez-Mueller, B., Rogers, Y.-H., Ross, M.C., 
Russ, C., Sanka, R.K., Sankar, P., Fah Sathirapongsasuti, J., Schloss, 
J.A., Schloss, P.D., Schmidt, T.M., Scholz, M., Schriml, L., Schubert, 
A.M., Segata, N., Segre, J.A., Shannon, W.D., Sharp, R.R., Sharpton, 
T.J., Shenoy, N., Sheth, N.U., Simone, G.A., Singh, I., Smillie, C.S., 
Sobel, J.D., Sommer, D.D., Spicer, P., Sutton, G.G., Sykes, S.M., 
Tabbaa, D.G., Thiagarajan, M., Tomlinson, C.M., Torralba, M., 
Treangen, T.J., Truty, R.M., Vishnivetskaya, T.A., Walker, J., Wang, 
L., Wang, Z., Ward, D.V., Warren, W., Watson, M.A., Wellington, C., 
Wetterstrand, K.A., White, J.R., Wilczek-Boney, K., Wu, Y., Wylie, 
K.M., Wylie, T., Yandava, C., Ye, L., Ye, Y., Yooseph, S., Youmans, 
B.P., Zhang, L., Zhou, Y., Zhu, Y., Zoloth, L., Zucker, J.D., Birren, 
B.W., Gibbs, R.A., Highlander, S.K., Methé, B.A., Nelson, K.E., 
Petrosino, J.F., Weinstock, G.M., Wilson, R.K. and White, O. and 
the Human Microbiome Project Consortium, 2012. Structure, 

















































































K. Bendjeddou et al.
304 Beneficial Microbes 12(3)
Ignacio, A., Fernandes, M.R., Rodrigues, V.A.A., Groppo, F.C., Cardoso, 
A.L., Avila-Campos, M.J. and Nakano, V., 2016. Correlation between 
body mass index and faecal microbiota from children. Clinical 
Microbiology and Infection 22: 258.e1-8. https://doi.org/10.1016/j.
cmi.2015.10.031
Ketaren, N.B., Marlida, Y., Arnim, A., Yuherman, Y. and Rusmarilin, 
H., 2016. Toxicity test pediocin N6 powder produced from isolates 
Pediococcus pentosaceus strain N6 on white mice. Journal of Food 
and Pharmaceutical Sciences 4(1).
Kheadr, E., Zihler, A., Dabour, N., Lacroix, C., Le Blay, G. and Fliss, 
I., 2010. Study of the physicochemical and biological stability of 
pediocin PA-1 in the upper gastrointestinal tract conditions using 
a dynamic in vitro model. Journal of Applied Microbiology 109: 
54-64. https://doi.org/10.1111/j.1365-2672.2009.04644.x
Köck, R., Becker, K., Cookson, B., Gemert-Pijnen, J.E. van, Harbarth, 
S., Kluytmans, J., Mielke, M., Peters, G., Skov, R.L., Struelens, M.J., 
Tacconelli, E., Torné, A.N., Witte, W. and Friedrich, A.W., 2010. 
Methicillin-resistant Staphylococcus aureus (MRSA): burden of 
disease and control challenges in Europe. Eurosurveillance 15: 
19688. https://doi.org/10.2807/ese.15.41.19688-en
Kumar, V. and Tiwari, S.K., 2017. Halocin HA1: An archaeocin produced 
by the haloarchaeon Haloferax larsenii HA1. Process Biochemistry 
61: 202-208. https://doi.org/10.1016/j.procbio.2017.06.010
Lagier, J.C., Million, M., Hugon, P., Armougom, F. and Raoult, D., 2012. 
Human gut microbiota: Repertoire and variations. Frontiers in 
Cellular and Infection Microbiology 2: 136. https://doi.org/10.3389/
fcimb.2012.00136
Lange, K., Buerger, M., Stallmach, A. and Bruns, T., 2016. Effects 
of antibiotics on gut microbiota. Digestive Diseases 34: 260-268. 
https://doi.org/10.1159/000443360
Langgartner, D., Peterlik, D., Foertsch, S., Füchsl, A.M., Brokmann, P., 
Flor, P.J., Shen, Z., Fox, J.G., Uschold-Schmidt, N., Lowry, C.A. and 
Reber, S.O., 2017. Individual differences in stress vulnerability: the 
role of gut pathobionts in stress-induced colitis. Brain, Behavior, 
and Immunity 64: 23-32. https://doi.org/10.1016/j.bbi.2016.12.019
Lee, A.S., de Lencastre, H., Garau, J., Kluytmans, J., Malhotra-
Kumar, S., Peschel, A. and Harbarth, S., 2018. Methicillin-resistant 
Staphylococcus aureus. Nature Reviews Disease Primers 4: 18033. 
https://doi.org/10.1038/nrdp.2018.33
Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., Mackey, V., Coy, D.H. 
and He, Q., 2019. The antimicrobial peptides and their potential 
clinical applications. American Journal of Translational Research 
11: 3919-3931.
Ley, R.E., Bäckhed, F., Turnbaugh, P., Lozupone, C.A., Knight, R.D. and 
Gordon, J.I., 2005. Obesity alters gut microbial ecology. Proceedings 
of the National Academy of Sciences of the USA 102: 11070-11075. 
https://doi.org/10.1073/pnas.0504978102
Ling, L.L., Schneider, T., Peoples, A.J., Spoering, A.L., Engels, I., 
Conlon, B.P., Mueller, A., Schäberle, T.F., Hughes, D.E., Epstein, 
S., Jones, M., Lazarides, L., Steadman, V.A., Cohen, D.R., Felix, 
C.R., Fetterman, K.A., Millett, W.P., Nitti, A.G., Zullo, A.M., Chen, 
C. and Lewis, K., 2015. A new antibiotic kills pathogens without 
detectable resistance. Nature 517: 455-459. https://doi.org/10.1038/
nature14098
Lussier, G., 1989. Histologie et histochimie. In: Payment, P. and Trudel, 
M. (eds.) Manuel de Techniques Virologiques. Presse de Université 
du Quebec, Sillery, Canada, pp. 63-179.
Maharshak, N., Packey, C.D., Ellermann, M., Manick, S., Siddle, J.P., 
Huh, E.Y., Plevy, S., Sartor, R.B. and Carroll, I.M., 2013. Altered 
enteric microbiota ecology in interleukin 10-deficient mice during 
development and progression of intestinal inflammation. Gut 
Microbes 4: 316-324. https://doi.org/10.4161/gmic.25486
Malachowa, N. and DeLeo, F.R., 2010. Mobile genetic elements of 
Staphylococcus aureus. Cellular and Molecular Life Sciences 67: 
3057-3071. https://doi.org/10.1007/s00018-010-0389-4
Meade, E., Slattery, M.A. and Garvey, M., 2020. Bacteriocins, 
potent antimicrobial peptides and the fight against multi drug 
resistant species: resistance is futile? Antibiotics 9: 32. https://doi.
org/10.3390/antibiotics9010032
Mishra, B., Reiling, S., Zarena, D. and Wang, G., 2017. Host defense 
antimicrobial peptides as antibiotics: design and application 
strategies. Current Opinion in Chemical Biology 38: 87-96. https://
doi.org/10.1016/j.cbpa.2017.03.014
Mizobuchi, S., Minami, J., Jin, F., Matsushita, O. and Okabe, A., 1994. 
Comparison of the virulence of methicillin-resistant and methicillin-
sensitive Staphylococcus aureus. Microbiology and Immunology 
38: 599-605. https://doi.org/10.1111/j.1348-0421.1994.tb01829.x
O’Connor, P.M., Kuniyoshi, T.M., Oliveira, R.P., Hill, C., Ross, R.P. and 
Cotter, P.D., 2020. Antimicrobials for food and feed; a bacteriocin 
perspective. Current Opinion in Biotechnology 61: 160-167. https://
doi.org/10.1016/j.copbio.2019.12.023
Oksanen, J., Blanchet, F.G., Friendly, M., Kindt, R., Legendre, P., 
McGlinn, D., Minchin, P.R., O’Hara, R.B., Simpson, G.L., Solymos, 
P., Stevens, M.H.H., Szoecs, E. and Wagner, H., 2019. vegan: 
Community Ecology Package. Available at: https://cran.r-project.
org/web/packages/vegan/index.html
Oksanen, J., Kindt, R. and Simpson, G.L., 2018. vegan3d: static and 
dynamic 3D plots for the ‘vegan’ package. Available at: https://rdrr.
io/cran/vegan3d/
Ołdak, A. and Zielińska, D., 2017. Bacteriocins from lactic acid 
bacteria as an alternative to antibiotics. Postepy Higieny 
I Medycyny Doswiadczalnej 71: 328-338. https ://doi.
org/10.5604/01.3001.0010.3817
O’Neill, J., 2016. Tackling drug-resistant infections globally: final 
report and recommendations. Review on antimicrobial resistance. 
Wellcome Trust. Available at: https://wellcomecollection.org/works/
thvwsuba
Petersen, P.J., Labthavikul, P., Jones, C.H. and Bradford, P.A., 2006. 
In vitro antibacterial activities of tigecycline in combination with 
other antimicrobial agents determined by chequerboard and time-
kill kinetic analysis. Journal of Antimicrobial Chemotherapy 57: 
573-576. https://doi.org/10.1093/jac/dki477
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., 
Peplies, J. and Glöckner, F.O., 2013. The SILVA ribosomal RNA 
gene database project: improved data processing and web-based 

















































































 Bacteriocins as therapeutics and microbiota regulators
Beneficial Microbes 12(3) 305
Renukuntla, J., Vadlapudi, A.D., Patel, A., Boddu, S.H.S. and Mitra, 
A.K., 2013. Approaches for enhancing oral bioavailability of peptides 
and proteins. International Journal of Pharmaceutics 447: 75-93. 
https://doi.org/10.1016/j.ijpharm.2013.02.030
Rizzatti, G., Lopetuso, L.R., Gibiino, G., Binda, C. and Gasbarrini, A., 
2017. Proteobacteria: A Common Factor in Human Diseases. BioMed 
Research International 2017. https://doi.org/10.1155/2017/9351507
Rognes, T., Flouri, T., Nichols, B., Quince, C. and Mahé, F., 2016. 
VSEARCH: a versatile open source tool for metagenomics. PeerJ 
4: e2584. https://doi.org/10.7717/peerj.2584
Ruppé, E., Burdet, C., Grall, N., de Lastours, V., Lescure, F.-X., 
Andremont, A. and Armand-Lefèvre, L., 2018. Impact of antibiotics 
on the intestinal microbiota needs to be re-defined to optimize 
antibiotic usage. Clinical Microbiology and Infection 24: 3-5. https://
doi.org/10.1016/j.cmi.2017.09.017
Sahoo, T.K., Jena, P.K., Prajapati, B., Gehlot, L., Patel, A.K. and Seshadri, 
S., 2017. In vivo assessment of immunogenicity and toxicity of the 
bacteriocin TSU4 in BALB/c mice. Probiotics and Antimicrobial 
Proteins 9: 345-354. https://doi.org/10.1007/s12602-016-9249-3
Schloss, P.D., Westcott, S.L., Ryabin, T., Hall, J.R., Hartmann, M., 
Hollister, E.B., Lesniewski, R.A., Oakley, B.B., Parks, D.H., Robinson, 
C.J., Sahl, J.W., Stres, B., Thallinger, G.G., Van Horn, D.J. and Weber, 
C.F., 2009. Introducing mothur: open-source, platform-independent, 
community-supported software for describing and comparing 
microbial communities. Applied and Environmental Microbiology 
75: 7537-7541. https://doi.org/10.1128/AEM.01541-09
Schwiertz, A., Taras, D., Schäfer, K., Beijer, S., Bos, N.A., Donus, C. 
and Hardt, P.D., 2010. Microbiota and SCFA in lean and overweight 
healthy subjects. Obesity 18: 190-195. https://doi.org/10.1038/
oby.2009.167
Seedorf, H., Griffin, N.W., Ridaura, V.K., Reyes, A., Cheng, J., Rey, F.E., 
Smith, M.I., Simon, G.M., Scheffrahn, R.H., Woebken, D., Spormann, 
A.M., Van Treuren, W., Ursell, L.K., Pirrung, M., Robbins-Pianka, A., 
Cantarel, B.L., Lombard, V., Henrissat, B., Knight, R. and Gordon, 
J.I., 2014. Bacteria from diverse habitats colonize and compete 
in the mouse gut. Cell 159: 253-266. https://doi.org/10.1016/j.
cell.2014.09.008
Seo, M.-D., Won, H.-S., Kim, J.-H., Mishig-Ochir, T. and Lee, B.-
J., 2012. Antimicrobial peptides for therapeutic applications: a 
review. Molecules 17: 12276-12286. https://doi.org/10.3390/
molecules171012276
Sobotta, J. and Welsch, U., 2000. Atlas d’histologie. Lavoisier. ed, Tech 
& Doc, Paris, France.
Spencer, J.D., Schwaderer, A.L., Becknell, B., Watson, J. and Hains, D.S., 
2014. The innate immune response during urinary tract infection 
and pyelonephritis. Pediatric Nephrology 29: 1139-1149. https://
doi.org/10.1007/s00467-013-2513-9
Sweeney, T.E. and Morton, J.M., 2013. The human gut microbiome: 
a review of the effect of obesity and surgically induced weight 
loss. JAMA Surgery 148: 563-569. https://doi.org/10.1001/
jamasurg.2013.5
Turner, N.A., Sharma-Kuinkel, B.K., Maskarinec, S.A., Eichenberger, 
E.M., Shah, P.P., Carugati, M., Holland, T.L. and Fowler, V.G., 2019. 
Methicillin-resistant Staphylococcus aureus: an overview of basic 
and clinical research. Nature Reviews Microbiology 17: 203-218. 
https://doi.org/10.1038/s41579-018-0147-4
Vieco-Saiz, N., Belguesmia, Y., Raspoet, R., Auclair, E., Gancel, F., 
Kempf, I. and Drider, D., 2019. Benefits and inputs from lactic 
acid bacteria and their bacteriocins as alternatives to antibiotic 
growth promoters during food-animal production. Frontiers in 
Microbiology 10: 57. https://doi.org/10.3389/fmicb.2019.00057
Waite, D.W., Vanwonterghem, I., Rinke, C., Parks, D.H., Zhang, Y., 
Takai, K., Sievert, S.M., Simon, J., Campbell, B.J., Hanson, T.E., 
Woyke, T., Klotz, M.G. and Hugenholtz, P., 2017. Comparative 
genomic analysis of the class Epsilonproteobacteria and proposed 
reclassification to Epsilonbacteraeota (phyl. nov.). Frontiers in 
Microbiology 8: 682. https://doi.org/10.3389/fmicb.2017.00682
 h
ttp
s:
//w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
20
.0
15
5 
- 
T
hu
rs
da
y,
 N
ov
em
be
r 
04
, 2
02
1 
1:
09
:4
4 
A
M
 -
 U
ni
ve
rs
ité
 d
e 
L
iè
ge
 I
P 
A
dd
re
ss
:1
39
.1
65
.3
1.
39
 
 h
ttp
s:
//w
w
w
.w
ag
en
in
ge
na
ca
de
m
ic
.c
om
/d
oi
/p
df
/1
0.
39
20
/B
M
20
20
.0
15
5 
- 
T
hu
rs
da
y,
 N
ov
em
be
r 
04
, 2
02
1 
1:
09
:4
4 
A
M
 -
 U
ni
ve
rs
ité
 d
e 
L
iè
ge
 I
P 
A
dd
re
ss
:1
39
.1
65
.3
1.
39
 
